PARSIPPANY, N.J., Oct. 12, 2012 /PRNewswire/ -- Watson
Pharmaceuticals, Inc. (NYSE: WPI) today announced that its
subsidiary Watson Laboratories, Inc. – Florida has received approval from the U.S.
Food and Drug Administration (FDA) on its Abbreviated New Drug
Application (ANDA) for Trospium Chloride Extended-release Capsules,
the generic equivalent to Allergan's Sanctura XR®.
Watson intends to begin shipping the product immediately. Sanctura
XR® is indicated for the treatment of overactive bladder
(OAB) with symptoms of urge urinary incontinence, urgency and
urinary frequency.
For the 12 months ending July 31,
2012, Sanctura XR® had total U.S. sales of
approximately $67 million according
to IMS Health data.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is an integrated global
specialty pharmaceutical company. The Company is engaged in
the development, manufacturing, marketing and distribution of
generic pharmaceuticals and specialized branded pharmaceutical
products focused on Urology and Women's Health. The Company
is also developing biosimilar products in Women's Health and
Oncology. Additionally, Watson distributes generic and
branded pharmaceuticals through its Anda, Inc. distribution
business. Watson has operations in many of the world's
established and growing international markets.
For press release and other company information, visit Watson
Pharmaceuticals' Web site at http://www.watson.com.
Forward-Looking Statement
Statements contained in this press release that refer to
non-historical facts are forward-looking statements that reflect
Watson's current perspective of existing information as of the date
of this release. It is important to note that Watson's goals and
expectations are not predictions of actual performance. Actual
results may differ materially from Watson's current expectations
depending upon a number of factors, risks and uncertainties
affecting Watson's business. These factors include, among others,
the impact of competitive products and pricing; the timing and
success of product launches; difficulties or delays in
manufacturing; the availability and pricing of third party sourced
products and materials; successful compliance with FDA and other
governmental regulations applicable to Watson and its third party
manufacturers' facilities, products and/or businesses; changes in
the laws and regulations, including Medicare and Medicaid,
affecting among other things, pricing and reimbursement of
pharmaceutical products; and such other risks and uncertainties
detailed in Watson's periodic public filings with the Securities
and Exchange Commission, including but not limited to Watson's
Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and Watson's Annual Report on Form
10-K for the year ended December 31,
2011. Except as expressly required by law, Watson disclaims
any intent or obligation to update these forward-looking
statements.
Sanctura XR® is a registered trademark of Allergan,
Inc.
CONTACTS:
|
Investors:
|
|
Lisa
DeFrancesco
|
|
(862)
261-7152
|
|
|
|
Media:
|
|
Charlie
Mayr
|
|
(862)
261-8030
|
(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)
SOURCE Watson Pharmaceuticals, Inc.